Lisata Therapeutics to Present at LD Micro Main Event XIXOctober 13, 2025 8:00 AM EDT | Source: LD MicroBasking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) -  Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corpora ...

Core Insights - Lisata Therapeutics Inc has entered a collaboration with Catalent to leverage its lead molecule, certepetide, across various cancer types and treatment modalities [1] Revenue Potential - The Catalent deal is described as having "unlimited revenue potential," particularly in the rapidly growing antibody-drug conjugate (ADC) class in oncology [2] - Major players in the industry are actively developing ADCs and seeking ways to enhance their efficacy [2] Partnership Details - The arrangement with Catalent is non-exclusive, allowing Lisata to partner with other companies in the ADC space [3] - This partnership introduces a new therapeutic modality, as certepetide has not been tested specifically with ADCs prior to this collaboration [4] Validation of Technology - The collaboration marks the first instance of a third party using a certepetide-related molecule conjugated to another molecule, validating the hypothesis of co-administration or conjugation benefits [5] Strategic Vision - The strategic vision for certepetide is to exploit its broad applicability across various cancers and treatment modalities, primarily through partnerships [6] - Collaborating with a well-established company like Catalent is seen as a significant advancement for Lisata, which recognizes its limitations as a small company [7] Future Partnerships - Lisata is actively seeking additional partnerships to further exploit the applicability of certepetide and is open to evaluating different transaction types [8]

By Karen Roman Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform. The partnership is a validation of certepetide’s versatility and positions Lisata’s technology within a leading ADC platform, the company stated. Catalent acquires non-exclusive rights to develop and commercialize products with certepe ...

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study results provide proof-of-concept support for leveraging certepetide-related biology through its use as an ADC payload BASKING RIDGE, N.J. and TAMPA, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innov ...

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions BASKING RIDGE, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced encouraging preliminary data from the pancreatic ductal adenoca ...

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [3] - The company's investigational drug, certepetide, is designed to enhance the targeting and penetration of anti-cancer drugs into solid tumors through a novel uptake pathway [3] Upcoming Presentation - David J. Mazzo, Ph.D., President and CEO of Lisata, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025 [1] - The on-demand recording of Dr. Mazzo's presentation will be available starting September 5, 2025, at 7:00 a.m. Eastern Time [2] Future Expectations - Lisata anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into the fourth quarter of 2026 [3] - The company has established significant commercial and R&D partnerships based on its CendR Platform technology [3]

Core Viewpoint - Lisata Therapeutics, Inc. is set to report its financial results for Q2 2025 on August 7, 2025, and will host a conference call to discuss these results [1]. Group 1: Financial Reporting - The financial results for the second quarter ended June 30, 2025, will be announced after the close of trading on August 7, 2025 [1]. - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the financial results [1]. Group 2: Conference Call Participation - Interested participants must register for the conference call via a provided link and will receive an email with dial-in options [2]. - Participants are encouraged to join the call 15 minutes early to avoid delays [2]. Group 3: Webcast Availability - A live webcast of the conference call will be available on Lisata's website and can be replayed for 12 months starting two hours after the call concludes [3]. Group 4: Company Overview - Lisata Therapeutics is focused on developing innovative therapies for advanced solid tumors and other serious diseases [4]. - The company's investigational drug, certepetide, aims to enhance the targeting and penetration of anti-cancer drugs in solid tumors [4]. - Lisata has established significant commercial and R&D partnerships based on its CendR Platform technology and anticipates announcing multiple milestones in the next 1.5 years [4]. - The company expects its capital to fund operations into Q4 2026, covering anticipated data milestones from ongoing and planned clinical trials [4].

Core Insights - Lisata Therapeutics and WARPNINE have completed patient enrollment in the Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC) [1][2] - The trial is significant as it targets an earlier stage of PDAC, where immunotherapy has been largely ineffective [2] - Preliminary data from the trial presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate after four treatment cycles [3][4] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [7] - Certepetide, the company's proprietary product candidate, is designed to enhance the delivery of anti-cancer drugs to solid tumors and has shown favorable safety and clinical activity in trials [6][7] - The company has received multiple designations for certepetide, including Fast Track and Orphan Drug Designations for pancreatic cancer in the U.S. and E.U. [6] Trial Details - The iLSTA trial is randomized, single-blind, and conducted at St John of God Subiaco Hospital, a leading center for clinical research in Australia [2][3] - Participants were divided into three cohorts, with varying combinations of standard-of-care chemotherapy and immunotherapy [2] - The trial aims to assess the efficacy of certepetide in improving treatment outcomes for patients with locally advanced PDAC [2][4] Preliminary Data Highlights - After four treatment cycles, 13 out of 20 participants showed a partial response, and one participant exhibited a complete response [3] - 16 out of 20 participants experienced a decrease in CA19-9 levels, a tumor marker, with several showing significant reductions [3] - No participants showed an increase in tumor size, indicating a positive response to the treatment [3] Collaboration and Support - The collaboration between Lisata and WARPNINE combines global expertise with local clinical execution to address urgent needs in pancreatic cancer treatment [2] - AstraZeneca is involved in providing drug supply, enhancing the trial's operational capabilities [2] - The successful completion of patient enrollment reflects the commitment of both organizations to advance treatment options for patients with PDAC [4]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]